Bristol Myers Squibb Partners with BioNTech in $11.1 Billion Deal for Dual-Target Cancer Immunotherapy
Bristol Myers Squibb will pay BioNTech $1.5 billion upfront plus $2 billion in anniversary payments through 2028 for a 50% partnership in BNT327, a bispecific antibody targeting both PD-L1 and VEGF proteins.
Pfizer Strikes $6 Billion Deal with 3SBio as RemeGen Raises HK$796 Million in Premium Placement
• Pfizer has completed a record-breaking $6 billion acquisition deal with Chinese biopharmaceutical company 3SBio, energizing China's innovative drug industry and potentially driving further valuations upward. • RemeGen successfully raised HK$796 million through a premium placement, demonstrating strong investor confidence following the successful out-licensing of its RC18 asset. • The transactions highlight the growing momentum in China's biotech sector, with 3SBio's valuation expected to continue rising while competitor Akeso may face downward pressure. • China's 11th batch of national Volume-Based Procurement (VBP) rules are expected to include optimizations balancing competitive bidding prices with drug quality standards.
Summit Therapeutics' Ivonescimab Shows Promising Results in Phase 3 NSCLC Trial
Summit Therapeutics reported statistically significant improvement in progression-free survival for ivonescimab plus chemotherapy versus BeiGene's Tevimbra combination in advanced squamous non-small cell lung cancer.
Akeso Secures FDA Approval for Novel Cancer Drug While Partner Summit Therapeutics Faces Sharp Stock Decline
Akeso has received FDA approval for its first internally developed cancer therapeutic, marking a significant milestone for the Chinese biopharmaceutical company's expansion into the US market.
Summit's Ivonescimab Shows Promise in Phase III Trial Against Established Lung Cancer Therapies
Summit Therapeutics and Akeso's bispecific antibody ivonescimab demonstrated superior progression-free survival compared to BeiGene's tislelizumab in squamous non-small cell lung cancer patients, adding to previous positive results against Merck's Keytruda.
Akeso Reports Positive Phase 3 Results for Ivonescimab in Lung Cancer, Building on Recent FDA Approval Success
Akeso announced positive Phase 3 results for ivonescimab, a novel PD-1/VEGF bispecific antibody, demonstrating superior tumor progression control when combined with chemotherapy compared to PD-1 inhibitor plus chemotherapy in lung cancer patients.
BioNTech's BNT327 Shows Promising 85% Response Rate in First-Line Treatment for Extensive-Stage SCLC
BNT327, a bispecific antibody targeting both PD-L1 and VEGF-A, demonstrated an 85.4% confirmed response rate when combined with chemotherapy in extensive-stage small cell lung cancer patients.
Pipeline Progress: Over 25 New Therapies in Development for Metastatic Liver Cancer
• DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options. • Several promising clinical trials are underway in 2025, including studies evaluating novel combinations such as AK104 plus lenvatinib, tislelizumab with lenvatinib, and triplet therapy of nivolumab, relatlimab and bevacizumab. • Key emerging therapies include exoASO-STAT6 targeting tumor-associated macrophages, STP705 dual TGF-ß1/COX-2 inhibitor, and ONCR-177, an oncolytic viral immunotherapy expressing five transgenes to fight tumors through multiple mechanisms.
First-in-Class IL-4Rα/ST2 Bispecific Antibody AK139 Advances to Clinical Development for Inflammatory Diseases
• Akeso's AK139, the world's first IL-4Rα/ST2 bispecific antibody, receives IND acceptance from China's NMPA for respiratory and skin diseases. • The novel dual-targeting mechanism simultaneously blocks IL-4/IL-13 and IL-33/ST2 inflammatory pathways, showing superior efficacy compared to single-target therapies in preclinical studies. • Preclinical data demonstrates AK139's strong dual-specific binding activity, promising pharmacological effects, and favorable safety profile, positioning it as a potential breakthrough therapy.
Akeso Completes Patient Enrollment in Phase III Trial Comparing Ivonescimab for First-Line Squamous NSCLC Treatment
Akeso has completed enrollment for the HARMONi-6 Phase III trial comparing ivonescimab plus chemotherapy to tislelizumab plus chemotherapy for first-line squamous non-small cell lung cancer treatment.